Baxdrostat: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. dru@adis.com.
None:
Baxdrostat (BAXFENDY™) is a first-in-class, highly selective and potent aldosterone synthase inhibitor being developed by AstraZeneca for the treatment of hypertension, chronic kidney disease (CKD) and primary aldosteronism, and for the prevention of heart failure. On 15 May 2026, baxdrostat received its first approval in the USA for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure (BP) in adults who are not adequately controlled on other agents. This article summarizes the milestones in the development of baxdrostat leading to this first approval for hypertension.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Bioequivalence studies: Biowaivers
Clinical Trials: Overview
Adrenergic Antagonists: ɑ and β-Receptor Blockers

